Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia

Bempedoic acid (Nilemdo, Daiichi Sankyo) is 'indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

• in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,

• alone or in combination with other lipid-lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated'.

Bempedoic acid–ezetimibe (Nustendi, Daiichi Sankyo) is 'indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

• in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe,

• alone in patients who are either statin intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone,

• in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin'.